CA2979293C - Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) - Google Patents

Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) Download PDF

Info

Publication number
CA2979293C
CA2979293C CA2979293A CA2979293A CA2979293C CA 2979293 C CA2979293 C CA 2979293C CA 2979293 A CA2979293 A CA 2979293A CA 2979293 A CA2979293 A CA 2979293A CA 2979293 C CA2979293 C CA 2979293C
Authority
CA
Canada
Prior art keywords
treatment
obesity
diabetes
type
pancreatic endocrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2979293A
Other languages
English (en)
French (fr)
Other versions
CA2979293A1 (en
Inventor
Timothy J. Kieffer
Jennifer E. BRUIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CCS Ventures Ltd
Original Assignee
CCS Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CCS Ventures Ltd filed Critical CCS Ventures Ltd
Publication of CA2979293A1 publication Critical patent/CA2979293A1/en
Application granted granted Critical
Publication of CA2979293C publication Critical patent/CA2979293C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2979293A 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) Active CA2979293C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131540P 2015-03-11 2015-03-11
US62/131,540 2015-03-11
PCT/CA2016/000072 WO2016141460A1 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Publications (2)

Publication Number Publication Date
CA2979293A1 CA2979293A1 (en) 2016-09-15
CA2979293C true CA2979293C (en) 2022-01-04

Family

ID=56879832

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979293A Active CA2979293C (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Country Status (7)

Country Link
US (2) US10772917B2 (2)
EP (1) EP3268016B1 (2)
JP (1) JP6847044B2 (2)
CN (1) CN107530379A (2)
AU (1) AU2016228894B2 (2)
CA (1) CA2979293C (2)
WO (1) WO2016141460A1 (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951136B2 (en) 2017-12-12 2024-04-09 The Regents Of The University Of California Preservation of pancreatic islet grafts in the extrahepatic space
WO2019142883A1 (ja) 2018-01-18 2019-07-25 第一三共株式会社 ジヒドロインドリジノン誘導体
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
AU2020279820B2 (en) 2019-05-22 2026-04-23 The Cleveland Clinic Foundation Generating dorsal foregut, and anterior domain, endoderm cells
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
KR20090115984A (ko) * 2001-11-09 2009-11-10 아르테셀 사이언스, 인크. 지방 조직에서 유래된 기질세포의 내분비 췌장 분화 및 이의 용도
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
JP2005537803A (ja) * 2002-09-06 2005-12-15 アムサイト インコーポレーティッド Ｃｄ５６陽性ヒト成体膵臓内分泌前駆細胞
WO2005001080A2 (en) 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
JP2006149380A (ja) * 2004-10-27 2006-06-15 Kobe Univ 遺伝子改変動物の新規用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CN102016582A (zh) * 2006-10-31 2011-04-13 国家干细胞控股公司 鉴别、分离和利用来自成人胰腺的内分泌祖细胞的方法
TWI609702B (zh) * 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
CA2723820A1 (en) * 2008-05-09 2009-11-12 Vistagen Therapeutics, Inc. Pancreatic endocrine progenitor cells derived from pluripotent stem cells
AU2010212823B2 (en) * 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
PL2494035T3 (pl) 2009-10-29 2018-07-31 Janssen Biotech, Inc. Pluripotencjalne komórki macierzyste
WO2011160066A1 (en) * 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
KR20190027969A (ko) * 2010-08-12 2019-03-15 얀센 바이오테크 인코포레이티드 췌장 내분비 전구 세포를 이용한 당뇨병의 치료
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Also Published As

Publication number Publication date
US10772917B2 (en) 2020-09-15
US20180055890A1 (en) 2018-03-01
EP3268016A1 (en) 2018-01-17
AU2016228894B2 (en) 2021-03-04
AU2016228894A1 (en) 2017-11-02
JP6847044B2 (ja) 2021-03-24
EP3268016A4 (en) 2018-12-12
CN107530379A (zh) 2018-01-02
EP3268016B1 (en) 2021-04-28
CA2979293A1 (en) 2016-09-15
US20210015872A1 (en) 2021-01-21
WO2016141460A1 (en) 2016-09-15
JP2018507889A (ja) 2018-03-22

Similar Documents

Publication Publication Date Title
CA2979293C (en) Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
Rose et al. Metabolic control through glucocorticoid hormones: an update
Munk et al. Senescence-associated microRNAs
Corchero et al. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics
Juvet et al. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning
Nafea et al. Immunoisolating semi-permeable membranes for cell encapsulation: focus on hydrogels
JOP20200202A1 (ar) اجسام مضادة بشرية لمستقبل الجلوكاجون
WO2015048346A3 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2017011422A (es) Composiciones y metodos para inhibir la expresion del gen del factor xii.
WO2012021698A3 (en) Treatment of diabetes with pancreatic endocrine precursor cells
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
WO2013149258A3 (en) Compositions and methods for treating or preventing metabolic syndrome disorders
WO2011017151A3 (en) Pairing processes for preparing alloreactive cytotoxic t cells
WO2013056049A3 (en) Tubular prostheses
EP3202409A4 (en) Composition, cell construct, islet transplant kit, islet cell transplant therapeutic agent and blood sugar reducing agent, composition including islets, kit including islets, and islet transplant therapeutic agent and blood sugar reducing agent
MX2016009102A (es) Composiciones de enolasa 1 (eno1) y sus usos.
WO2014066400A3 (en) Methods for the effective treatment of metastatic cancer
WO2014014819A3 (en) Methods of treating glucose metabolism disorders
新留琢郎 Diagnostic and therapeutic applications of biocompatible gold nanorods: Original research article: PEG-modified gold nanorods with a stealth character for in vivo applications, 2006.
Lin Iodine-125
WO2014132137A3 (en) Transgenic cell selection
Hallakou-Bozec et al. Imeglimin preserves beta cell function and mass in male zucker diabetic fatty rats
Bhat Uncovering the Therapeutic Potential of MicroRNA: A new Paradigm to Unmet Medical Need
樫美和子 Hyperglycemia induces abnormal gene expression in hematopoietic stem cells and their progeny in diabetic neuropathy.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250107